Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest

Aytu BioPharma, Inc. (NASDAQ:AYTU) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 126,800 shares, a growth of 7.1% from the November 30th total of 118,400 shares. Currently, 2.1% of the company’s shares are sold short. Based on an average daily volume of 37,000 shares, the short-interest ratio is presently 3.4 days.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in shares of Aytu BioPharma by 54.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock valued at $69,000 after acquiring an additional 8,311 shares during the period. Stonepine Capital Management LLC raised its stake in shares of Aytu BioPharma by 6.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after acquiring an additional 28,489 shares during the period. Finally, Armistice Capital LLC purchased a new stake in shares of Aytu BioPharma in the 2nd quarter valued at approximately $736,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Price Performance

Shares of AYTU stock opened at $1.70 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.80. The firm’s 50-day moving average is $1.66 and its two-hundred day moving average is $2.25. Aytu BioPharma has a 12 month low of $1.30 and a 12 month high of $3.45. The company has a market capitalization of $10.45 million, a PE ratio of -1.38 and a beta of -1.40.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.